Global Custom Market Research Reports Provider Company

phone

Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026

  • Published Date: 04 May 2018
  • Number of Pages: 108
  • Category: Pharmaceuticals
  • Country: Global
Parkinsons Disease: Global Drug Forecast and Market Analysis to 2026

Summary

Parkinsons disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism-neurological disorders that lead to movement problems. While the exact cause of Parkinsons disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.

Current treatments centre on the management of dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the Parkinsons market for the past half century. These therapies provide the best relief of symptoms at a low annual cost of therapy (ACOT), with Sinemet (carbidopa/levodopa) and Madopar (benserazide/levodopa) being the two most popular branded drugs.

GlobalData estimates that drug sales for PD in 2016 were approximately $3.1B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $8.8B at a CAGR of 11.1%. This growth will be driven by the launch of thirteen late-stage pipeline products. The two highest selling drugs are expected to be Roche/Prothenas PRX-002and Acordas CVT-301, which both address some of the unmet needs in the market.

Key Questions Answered

- What are the key PD treatments in 2016?
- When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?
- Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

- Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Publisher Name : GlobalData


1.1 List of Tables 6
1.2 List of Figures 6
2 Parkinsons Disease: Executive Summary 8
2.1 Parkinsons Market Forecast to Reach $8.8B by 2026 9
2.2 New Players Expected to Establish Themselves in the Forecast Period as Late-Stage Pipeline Assets Launched 10
2.3 Disease-Modifying Agents and Late-Stage Complications the Largest Unmet Needs in the PD Market 12
2.4 Treatments for Late-Stage Complications, Including Dyskinesia and Psychosis, Provide Companies with European and Japanese Opportunity 12
2.5 Biologics and Reformulations Expected to Drive Growth Pipeline 13
2.6 What Do Physicians Think? 14
3 Introduction 17
3.1 Catalyst 17
3.2 Related Reports 18
3.3 Upcoming Related Reports 18
4 Disease Overview 19
4.1 Etiology 19
4.1.1 Overview 19
4.1.2 Aging 19
4.1.3 Environmental Factors 19
4.1.4 Genetic Factors 20
4.2 Pathophysiology 21
4.2.1 Overview 21
4.2.2 Mechanisms of Cell Death 22
5 Epidemiology 25
5.1 Disease Background 25
5.2 Risk Factors and Comorbidities 25
5.3 Global and Historical Trends 26
5.3.1 US 28
5.3.2 5EU 28
5.3.3 Japan 29
5.4 Forecast Methodology 29
5.4.1 Sources 30
5.4.2 Sources Not Used 32
5.4.3 Forecast Assumptions and Methods 32
5.5 Epidemiological Forecast for PD (2016-2026) 36
5.5.1 Diagnosed Prevalent Cases of PD 36
5.5.2 Age-Specific Diagnosed Prevalent Cases of PD 37
5.5.3 Sex-Specific Diagnosed Prevalent Cases of PD 38
5.5.4 Diagnosed Prevalent Cases of PD by Clinical Staging 39
5.6 Discussion 40
5.6.1 Epidemiological Forecast Insight 40
5.6.2 Limitations of the Analysis 41
5.6.3 Strengths of the Analysis 42
6 Disease Management 43
6.1 Diagnosis and Treatment Overview 43
6.2 US 46
6.3 5EU 48
6.4 Japan 50
7 Competitive Assessment 53
7.1 Overview 53
8 Unmet Needs and Opportunity Assessment 55
8.1 Overview 55
8.2 Treatment of Motor Complications - Dyskinesia and OFF Episodes 57
8.3 Treatment of Non-motor Complications and Dementia 59
8.4 Neuroprotective/Disease-Modifying Agents 60
8.5 Improved Drug Formulations 62
9 Pipeline Assessment 64
9.1 Overview 64
9.2 Promising Drugs in Clinical Development 65
10 Current and Future Players 67
10.1 Overview 67
10.2 Trends in Corporate Strategy 68
10.3 AbbVie 69
10.4 Roche 69
10.5 Orion Pharma 70
10.6 Impax Pharmaceuticals 70
10.7 Acorda Therapeutics 71
10.8 Adamas Pharmaceuticals 71
10.9 UCB 72
10.10 Kyowa Hakko Kirin 72
10.11 Other Players 73
11 Market Outlook 74
11.1 Global Markets 74
11.1.1 Forecast 74
11.1.2 Drivers and Barriers - Global Issues 76
11.2 US 76
11.2.1 Forecast 76
11.2.2 Key Events 78
11.2.3 Drivers and Barriers 79
11.3 5EU 79
11.3.1 Forecast 79
11.3.2 Key Events 81
11.3.3 Drivers and Barriers 82
11.4 Japan 82
11.4.1 Forecast 82
11.4.2 Key Events 84
11.4.3 Drivers and Barriers 84
12 Appendix 85
12.1 Bibliography 85
12.2 Abbreviations 90
12.3 Methodology 92
12.3.1 Forecasting Methodology 92
12.3.2 Diagnosed Patients 93
12.3.3 Percent Drug-Treated Patients 93
12.3.4 Drugs Included in Each Therapeutic Class 93
12.3.5 Launch and Patent Expiry Dates 94
12.3.6 General Pricing Assumptions 95
12.3.7 Individual Drug Assumptions 96
12.3.8 Generic Erosion 101
12.3.9 Pricing of Pipeline Agents 101
12.4 Primary Research - KOLs [and Payers] Interviewed for This Report 102
12.4.1 KOLs 102
12.4.2 Payers 102
12.5 Primary Research - Prescriber Survey 103
12.6 About the Authors 104
12.6.1 Analyst 104
12.6.2 Therapy Area Director 104
12.6.3 Epidemiologist 105
12.6.4 Managing Epidemiologist 105
12.6.5 Global Director of Therapy Analysis and Epidemiology 106
12.6.6 Global Head and EVP of Healthcare Operations and Strategy 106
12.7 About GlobalData 107
12.8 Contact Us 107
12.9 Disclaimer 107

List Of Tables

1.1 List of Tables
Table 1: Parkinsons Disease: Key Metrics in the 7MM 8
Table 2: Risk Factors and Comorbidities for PD 26
Table 3: 7MM, Diagnosed Prevalent Cases of PD By Clinical Staging, Both Sexes, Ages 18 Years, N, 2016 40
Table 4: Treatment Guidelines for PD 45
Table 5: Country Profile - US 47
Table 6: Country Profile - 5EU 50
Table 7: Country Profile - Japan 52
Table 8: Leading Treatments for Parkinsons Disease, 2016 54
Table 9: Comparison of Therapeutic Classes in Development for Parkinsons Disease, 2016-2026 66
Table 10: AbbVies Disease Portfolio Assessment, 2018 69
Table 11: Roches Disease Portfolio Assessment, 2018 70
Table 12: Orion Pharmas Disease Portfolio Assessment, 2018 70
Table 13: Impax Pharmaceuticals Disease Portfolio Assessment, 2018 71
Table 14: Acorda Therapeutics Disease Portfolio Assessment, 2018 71
Table 15: Adamas Pharmaceuticals Disease Portfolio Assessment, 2018 72
Table 16: UCBs Disease Portfolio Assessment, 2018 72
Table 17: Kyowa Hakko Kirins Disease Portfolio Assessment, 2018 73
Table 18: Parkinsons Disease Market - Global Drivers and Barriers, 2016-2026 76
Table 19: Key Events Impacting Sales for Parkinsons Disease in the US, 2016-2026 78
Table 20: Parkinsons Disease Market - Drivers and Barriers in the US, 2016-2026 79
Table 21: Key Events Impacting Sales for Parkinsons Disease in the 5EU, 2016-2026 81
Table 22: Parkinsons Disease Market - Drivers and Barriers in the 5EU, 2016-2026 82
Table 23: Key Events Impacting Sales for Parkinsons Disease in Japan, 2016-2026 84
Table 24: Parkinsons Disease Market - Global Drivers and Barriers in Japan, 2016-2026 84
Table 25: Key Projected Launch Dates for Parkinsons disease 94
Table 26: Key Historical and Projected Patent Expiry Dates for Parkinsons Disease 95
Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 103

List Of Figures

1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Parkinsons Disease in 2016 and 2026 10
Figure 2: Analysis of the Company Portfolio Gap in Parkinsons Disease During the Forecast Period 11
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinsons Disease During the Forecast Period 14
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of PD, Ages 18 Years, 2016 27
Figure 5: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of PD, 2016-2026 31
Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of PD Clinical Staging, 2016-2026 32
Figure 7: Diagnosed Prevalent Cases of PD, 7MM, Both Sexes, 18 Years, N, 2016 37
Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages 18 Years, N, 2016 38
Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages 18 Years, N, 2016 39
Figure 10: Treatment Algorithm for Parkinsons Patients 45
Figure 11: Unmet Needs and Opportunities in Parkinsons Disease 56
Figure 12: Pharmacokinetics of Levodopa 57
Figure 13: Overview of the Development Pipeline in Parkinsons Disease 64
Figure 14: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period 65
Figure 15: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinsons Disease During the Forecast Period 66
Figure 16: Analysis of the Company Portfolio Gap in Parkinsons Disease During the Forecast Period 68
Figure 17: Global (7MM) Sales Forecast by Country for Parkinsons Disease in 2016 and 2026 75
Figure 18: Sales Forecast by Class for Parkinsons Disease in the US in 2016 and 2026 77
Figure 19: Country Breakdown for Parkinsons Disease Sales in the 5EU in 2016 and 2026 80
Figure 20: Sales Forecast by Class for Parkinsons Disease in Japan in 2016 and 2026 83

Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027 Stroke is caused by the interruption of the blood supply to the brain, usually because a cerebral blood vessel ruptures

View Report

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026 Inflammatory bowel disease (IBD) refers to two chronic autoimmune diseases that cause intestinal inflammation: Crohns disease (CD) and ulcerative colitis (UC).

View Report

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026 Dry Eye Syndrome (DES) is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances,

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports